#1 Clinical Trials Search in Europe

ALXN1920

Clinical trials are studying ALXN1920 in people with primary membranous nephropathy (PMN). The main goal is to see whether ALXN1920 works better than placebo and to measure outcomes such as proteinuria, which is protein in the urine. The trial is looking at participants with a higher risk of disease progression.

Table of Contents

Trial overview

The available trial is a Phase 2 interventional study of ALXN1920 in people with primary membranous nephropathy (PMN).[1] It is designed to compare ALXN1920 with placebo in a small group of participants.[1]

The study aims to evaluate whether ALXN1920 can improve proteinuria, which means protein loss in the urine, in participants who are at high risk for disease progression.[1]

Who is being studied

The target population is people with PMN who are considered at high risk for the disease getting worse.[1] This focus matters because PMN can affect kidney function, and higher-risk patients may need closer study.

The trial plans to enroll 30 participants.[1] That is a small study size, which is common in early mid-stage clinical research.

Trial design and phase

This is an interventional study, which means researchers assign a treatment and then measure the results.[1] In this trial, participants receive either ALXN1920 or placebo.[1]

A placebo is a comparison product that does not contain the active study drug.[1] Using placebo helps researchers see whether changes are linked to ALXN1920 rather than to chance or other factors.

The study is listed as Authorised.[1] This means the trial has been approved to move forward.

What the trial is measuring

The main outcome is the change from baseline in proteinuria based on 24-hour UPCR.[1] Baseline means the starting point before treatment begins.

UPCR is a urine test used to estimate how much protein is lost in the urine over 24 hours.[1] A change in this value helps show whether the study treatment is affecting kidney-related protein loss.

The brief summary says the study is evaluating the efficacy of ALXN1920 compared with placebo.[1] Efficacy means how well a treatment works under study conditions.

What the study status means

The trial status is Authorised.[1] This suggests the study is ready or allowed to proceed, but the data provided do not show final results.

Because only one trial is listed, the current evidence base in this dataset is limited to this single Phase 2 study in PMN.[1]

Trial ID Phase Condition studied Status Enrollment
2025-520780-40-00 Phase 2 Primary Membranous Nephropathy (PMN) Authorised 30

FAQ

  • What is ALXN1920 being studied for? ALXN1920 is being studied in primary membranous nephropathy (PMN). The trial is testing whether it can improve proteinuria, which means lowering protein loss in the urine.
  • Who can take part in the ALXN1920 trial? The study is for participants with PMN who are at high risk for disease progression. This means the trial is focusing on people whose kidney disease may get worse.
  • What phase is the ALXN1920 trial? The study is a Phase 2 trial. Phase 2 trials usually look more closely at whether a treatment works and continue to check safety.
  • What is the main outcome being measured? The main outcome is the change from baseline in proteinuria based on 24-hour UPCR. Baseline means the starting point before treatment, and UPCR is a urine test that helps measure protein loss.
  • Is the study comparing ALXN1920 with another treatment? Yes. The trial is comparing ALXN1920 with placebo. A placebo looks like treatment but does not contain the active study drug.

Ongoing Clinical Trials on ALXN1920

  • A Study of ALXN1920 Compared to Placebo in Adults with Primary Membranous Nephropathy at High Risk for Disease Progression

    Recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    France Italy Spain

Glossary

  • Primary membranous nephropathy (PMN): A kidney disease that affects the filtering units of the kidneys and can cause protein to leak into the urine.
  • Proteinuria: Too much protein in the urine. This is a sign that the kidneys are not filtering normally.
  • 24-hour UPCR: A urine test used to measure protein loss over time. It helps researchers track how much protein is being lost in the urine.
  • Placebo: A treatment that looks like the study drug but has no active medicine. It is used for comparison.
  • Phase 2: A mid-stage clinical trial that looks more closely at whether a treatment works and continues to collect safety information.
  • Interventional study: A study where researchers give a treatment or placebo and then measure the results.
  • Enrollment: The number of people planned to join the trial.
  • Baseline: The starting point before treatment begins. Results are often compared with this point.
  • Disease progression: When a disease gets worse over time.
  • Authorized: The study has been approved to proceed.

References

  1. https://clinicaltrials.gov/study/2025-520780-40-00